Diabetic Gastroparesis Treatment Market Report

Diabetes impacts people of every age, gender, and location, making it a leading worldwide cause of death and illness. About 422 million people around the world have diabetes, with most living in low- and middle-income countries. Types 1 and 2 are the most prevalent forms of DM, each with established diagnostic criteria. An autoimmune response is believed to be the cause of type 1 diabetes when the body mistakenly attacks itself. This process damages the pancreatic cells responsible for producing insulin, which are known as beta cells. The process may continue for months or years before any symptoms become noticeable. Socio-economic, demographic, environmental, and genetic factors drive 96% of type 2 diabetes (T2D) cases worldwide. The main risk factor for type 2 diabetes is having a high BMI of 30.0 or above, which accounts for 52.2% of disability and mortality associated with the disease. The illness causes 1.5 million deaths each year. Dietary risks were followed by environmental/occupational, tobacco, physical inactivity, and alcohol risks. Approximately 1.28 billion adults worldwide aged 30-79 are facing hypertension, while more than 300 million people are currently dealing with the disease, leading to an increased demand for daily disease management by patients. Considering the age of patients aged 45–65 is crucial when seeking their viewpoints on self-management or treatments.

Additionally, leading manufacturers consistently invest in R&D programmes to provide novel ways to existing drug therapies. Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical business working to create medications that would help people with unmet medical requirements live longer and with a better quality of life, stated in April 2022, that it has enrolled the first patient in its PCS12852 Phase 2A clinical trial for patients with mild to severe gastroparesis. Metoclopramide, a dopamine D2 receptor antagonist, is the only pharmacological therapy for gastroparesis that the FDA has currently approved. It is only approved for treating diabetic gastroparesis.

Diabetic gastroparesis is a serious gastrointestinal disorder. However, a significant portion of the general population is unaware about the disease's symptoms and treatment options. A survey was done with 490 doctors from Asia, according to a research published in the Journal of Neurogastroenterology and motility in 2023. It was shown that above 41.7% of respondents had access to stomach emptying scintigraphy. Owing to a lack of public awareness, the majority of doctors had never diagnosed gastroparesis or had diagnosed less than 5 cases each year.

Furthermore, development of new treatments for diabetic gastroparesis, like stem cell therapies and microbiome-modulating drugs, requires a significant amount of financial resources. For instance, research for stem cell therapies must be thorough to guarantee both safety and effectiveness, with expenses surpassing US$1 billion for development and clinical trials. Similarly, in-depth research on gut flora interactions and long-term effects is necessary for microbiome-modulating drugs, resulting in high R&D costs. The increasing level of manufacturing complexities leads to higher costs, requiring specialized facilities and processes for the production of advanced therapies. Furthermore, the financial burden is often heightened by the large-scale, multi-phase studies conducted during clinical trials for these innovative treatments. The high costs of development may discourage investors and delay the release of innovative treatments to the market.

Strategic developments and product innovation in diabetic gastroparesis treatment focus on integrating advanced technologies and personalized therapies. Innovations like targeted biologics, real-time digital monitoring, and stem cell research aim to address both symptoms and underlying causes. These treatments are crucial as they offer hope for improved patient quality of life and symptom management. Addressing this complex condition effectively can enhance overall diabetes care and reduce long-term complications. For instance, Evoke Pharma, Inc., a specialty pharmaceutical firm focused primarily on treatments for gastrointestinal (GI) diseases with a focus on GIMOTI (metoclopramide) nasal spray, and EVERSANATM, announced in February 2023, that its abstract entitled “Reducing Real-World Healthcare Resource Utilization for Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide.

North America is anticipated to hold a significant market share in the diabetic gastroparesis treatment market owing to an ageing population and an increase in surgical procedures. Owing to its huge prediabetic population, favourable reimbursement rules, and increased awareness of the disease, the United States dominated the market. According to the CDC, 96 million individuals aged 18 and older have prediabetes accounting for 38.0% of the adult population in the United States. Furthermore, rising healthcare expenditures, an increasing number of hospitals, and the existence of well-established healthcare infrastructure all contribute to the region's market domination. Additionally, according to International Diabetes Federation (IDF) statistics from September 2023, an estimated over 51 million individuals in North America and the Caribbean region had diabetes in 2023, with this number expected to climb to 57 million by 2030 and 63 million by 2045. As a result, the rising incidence of diabetics is propelling the market forward.